{"name":"Laboratorios Rovi","slug":"laboratorios-rovi","ticker":"ROVI.MC","exchange":"Bolsa de Madrid","domain":"rovi.es","description":"Laboratorios Farmaceuticos Rovi SA is a Spanish pharmaceutical company.","hq":"Madrid, Spain","founded":1972,"employees":"1950","ceo":"Juan López-Belmonte Encina","sector":"Specialty Pharma / CDMO","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":59.4,"stockChange":-0.45,"stockChangePercent":-0.75,"marketCap":"$3.5B","metrics":{"revenue":868554916.5826945,"revenueGrowth":9.7,"grossMargin":63.4,"rdSpend":0,"netIncome":164067757.14060003,"cash":115183411.30710001,"dividendYield":1.39,"peRatio":25.2,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"Lorazepam patent cliff ($100.0M at risk)","drug":"Lorazepam","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Olanzapine patent cliff ($200.0M at risk)","drug":"Olanzapine","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Rovi Reports Fourth-Quarter and Full-Year 2023 Results","summary":"Rovi reported a net profit of €43.4 million for the fourth quarter of 2023, up 12% from the same period in 2022. The company's revenue for the full year 2023 reached €1.43 billion, a 10% increase from 2022.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"Rovi Signs Agreement with Pfizer to Manufacture and Distribute Generic Medicines","summary":"Rovi has signed a long-term agreement with Pfizer to manufacture and distribute generic medicines in the European market. The agreement is expected to generate significant revenue for Rovi in the coming years.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQVjRhUlVmc0hZNDVoZExqRDdRT0pfZ1dJNzE3NWJpSHhmcHlwaF9XbUZVbmVjSHlGYTVlYlNGc1F0cHQ4a0FjWUV0d3RlWGE4MFM5cnp2UFVhSDRGemN5S29pV1R6dklybi1fMU1UZUV1aGFZMEhsQ29RWlBBUC1SMnAxOG9lRkxTeDQ2VXlaLUM0RXB1cnE3SDhJNDUxUUZZd1dkS0FqVG9RdXZkclM4d2RTZ3doRWxYbUtUbXFpRzY?oc=5","date":"2025-02-13","type":"earnings","source":"Fierce Pharma","summary":"Rovi warns analyst profit consensus is too high, cites CDMO slowdown - Fierce Pharma","headline":"Rovi warns analyst profit consensus is too high, cites CDMO slowdown","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOVWtKLVVfY2VNdHRnVGNoX3JGTWlWemdBcDJIWS1OWExmQXEyV1VueWhXMkJmQkFJME9tUXhpYUhETFdyMVFZYU5veWN4cjlQZ2F5SWVsQVZ5a29oZlNhNVg3ZkU3ZmFKdFlsN2xSbm9ObHB2U2RfYW9ET0ktQjRTVlp3UkpCVzlqQ0lreElZZXR2eE1uT3dNRXh2YlZTVTc2dzRzanVkSWZSMk1DQzRNTGtR?oc=5","date":"2024-10-24","type":"pipeline","source":"Reuters","summary":"Spanish drugmaker Rovi to keep third-party manufacturing business - Reuters","headline":"Spanish drugmaker Rovi to keep third-party manufacturing business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNQi1aMEg4UV9rNk1iWGtvdThXdWJmb3VmN3o2UzBmXzA0T1dqMEJKWG1yZDhxZzJFbnBPcEIzdktfY1Y0d25kdmRtYWF2a0xyYU4yc01XQW5iVUdzM3BXTk10MFJ6UTljRXNwaVVyMUJzXzJTQ292RXFZaGoteTlOb0RtVG8wRENHZ194RWUyS29KTGdmclBxUXpidGg3WE9fMjhFbWJhZENmZURMS05fTkVmemRJdmdfWHp6R3VWZXBpdy02?oc=5","date":"2024-03-07","type":"pipeline","source":"Reuters","summary":"Rovi explores sale of unit that makes drugs for third parties - Reuters","headline":"Rovi explores sale of unit that makes drugs for third parties","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOcG42aV8zb0hsdXdrclpEYk9GV0xkb1RwRHpyZDVEdlhFTEd1ay03VWZZakFwZnoxNEFtNG9YeHN2OVpkWnM3T2xWcGN0R1F6SnR4UWdlWkc1NkR4dWxQMEhsd2MxbFoxUVBMS2pFUFg2VlZJcmxMZERNcnRvTC03N2sxdGNfV3h5OVE5b1ptRldsLTZyaGNON3M0b1dDajFENnhobUpvNnlpSWcxSEFENkktUWowY1NYakpTeDl1U091YkpkaDg1MkVjUHVaeTc0WXlr?oc=5","date":"2023-09-19","type":"pipeline","source":"Reuters","summary":"Moderna to cut mRNA drug substance production at Lonza facility - Reuters","headline":"Moderna to cut mRNA drug substance production at Lonza facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE1LNkJna2JQemVrQnRfd2lRT01Zb2tGUkp4MndNLTVtRVBsMV9GeHd6WDNjblNyZkl0UG5wTnN4TGdRclNkRThORWRPdUtybVYwTjFTaVJFRlk?oc=5","date":"2023-04-25","type":"pipeline","source":"Yahoo! Finance Canada","summary":"H. Lundbeck A/S (HLUN-B.CO) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"H. Lundbeck A/S (HLUN-B.CO) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPVGJnWWw2OTJQZzVFMXllSmtQWHRuNmI0d0NrcEp3VXVyVDNuQW9aaGM5TkNTZnFLRnd4bzE0TExXckRtbjItR0tnNkk2ZmFKelc3R21BRFZ2WkZOd1RZNUJaaTNPTGNGTzBYWHRhQ0NKZl93V0h0QnJIbmFHRTBDWDVBSUxSLUM4MjFJMlpyd1NQT0FFblZRTjlBTTctRlNxSFlSNjBNQVdzM0V0ajhiZk5GQVBFcThhNjV4bA?oc=5","date":"2021-04-12","type":"pipeline","source":"Reuters","summary":"Spanish drugmaker Rovi to make ingredients for Moderna COVID-19 vaccine - Reuters","headline":"Spanish drugmaker Rovi to make ingredients for Moderna COVID-19 vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE9XVHhhOEdWajhDamx1cHJFSzl0Y1VjamZ3d1N3bmRLal9ibDM3Y2M2eGprRzNNZ0Z3NDVaS1NXQWlXNEY0alFOMk1OQ3o1eUNqVTBlWA?oc=5","date":"2017-05-22","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Pharma Mar, S.A. (PHM.MC) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Pharma Mar, S.A. (PHM.MC) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE5fLTk1UGVUOC0wSHlxeDktVU1OWENwUHR5eXEySm5lV3N4RWJYbVlqYXU5UHByNmVra05WN0V5WWN5a0p3T2tKQ2dEUnV1WUtjWHB1Xw?oc=5","date":"2017-05-20","type":"pipeline","source":"Yahoo Finance UK","summary":"Pharma Mar, S.A. (PHM.MC) stock price, news, quote and history - Yahoo Finance UK","headline":"Pharma Mar, S.A. (PHM.MC) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Lorazepam","drugSlug":"lorazepam","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":100000000},{"drugName":"Olanzapine","drugSlug":"olanzapine","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":200000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Merck KGaA","Teva Pharmaceutical Industries","Mylan N.V."],"therapeuticFocus":["Oncology","Neurology","Infectious Diseases"],"financials":{"source":"yahoo_finance","revenue":892230140.9007001,"revenuePeriod":"2024-12-31","revenueHistory":[{"period":"2024-12-31","value":892230140.9007001},{"period":"2023-12-31","value":969052570.8687},{"period":"2022-12-31","value":955254673.6614001},{"period":"2021-12-31","value":757800234.2511001}],"grossProfit":558815421.0078001,"grossProfitHistory":[{"period":"2024-12-31","value":558815421.0078001},{"period":"2023-12-31","value":575099299.5255},{"period":"2022-12-31","value":607024533.1959001},{"period":"2021-12-31","value":449558411.57460004}],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":46057243.0275,"operatingIncome":209748831.9435,"operatingIncomeHistory":[{"period":"2024-12-31","value":209748831.9435},{"period":"2023-12-31","value":257306074.97220004},{"period":"2022-12-31","value":298890187.15500003},{"period":"2021-12-31","value":212017523.53410003}],"netIncome":159907710.4083,"netIncomeHistory":[{"period":"2024-12-31","value":159907710.4083},{"period":"2023-12-31","value":198989486.1405},{"period":"2022-12-31","value":233258177.7567},{"period":"2021-12-31","value":178828271.17110002}],"eps":2.676097,"epsHistory":[{"period":"2024-12-31","value":2.676097},{"period":"2023-12-31","value":3.287042},{"period":"2022-12-31","value":3.73},{"period":"2021-12-31","value":2.76}],"cash":31759345.819800004,"cashHistory":[{"period":"2024-12-31","value":31759345.819800004},{"period":"2023-12-31","value":29581775.724600002},{"period":"2022-12-31","value":145963785.1635},{"period":"2021-12-31","value":115695093.5505}],"totalAssets":971988318.5346001,"totalLiabilities":292619159.1126,"totalDebt":133656542.16300002,"equity":668257009.8804001,"operatingCashflow":161539719.7554,"operatingCashflowHistory":[{"period":"2024-12-31","value":161539719.7554},{"period":"2023-12-31","value":132297897.30210002},{"period":"2022-12-31","value":277572430.1286},{"period":"2021-12-31","value":174580607.61630002}],"capex":-72685747.72170001,"capexHistory":[{"period":"2024-12-31","value":-72685747.72170001},{"period":"2023-12-31","value":-64470794.44410001},{"period":"2022-12-31","value":-60032710.32840001},{"period":"2021-12-31","value":-47827102.84200001}],"freeCashflow":88853972.0337,"dividendsPaid":-65947429.959300004,"buybacks":-104799065.50440001,"employees":1950,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2026-03-31","revenue":null,"epsBasic":0.18532,"netIncome":null,"rdExpense":null,"epsDiluted":0.18532,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":89314252.4079,"ebitda":98039719.7046,"period":"2025-09-30","revenue":245879673.09390002,"epsBasic":null,"netIncome":67790887.90470001,"rdExpense":null,"epsDiluted":null,"grossProfit":172678738.4559,"operatingIncome":89142523.4358},{"sga":null,"ebit":32098130.866800003,"ebitda":40821261.7149,"period":"2025-06-30","revenue":186563084.2614,"epsBasic":null,"netIncome":25274532.7305,"rdExpense":null,"epsDiluted":null,"grossProfit":122996495.4255,"operatingIncome":32536214.979300003},{"sga":null,"ebit":27427570.1154,"ebitda":35933411.243700005,"period":"2025-03-31","revenue":180948598.27560002,"epsBasic":0.353912,"netIncome":21146028.054300003,"rdExpense":null,"epsDiluted":0.353912,"grossProfit":105605140.2714,"operatingIncome":26981308.432800002},{"sga":null,"ebit":144074766.4704,"ebitda":161094626.2971,"period":"2024-12-31","revenue":507491822.83590007,"epsBasic":1.81,"netIncome":108102803.82480001,"rdExpense":null,"epsDiluted":1.81,"grossProfit":329860981.5723,"operatingIncome":143769859.92810002},{"sga":null,"ebit":105526869.2433,"ebitda":113870327.1939,"period":"2024-09-30","revenue":274855140.40680003,"epsBasic":null,"netIncome":80779205.67210001,"rdExpense":null,"epsDiluted":null,"grossProfit":190786215.10590002,"operatingIncome":105372663.6357}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":59.4,"previousClose":59.85,"fiftyTwoWeekHigh":86.7,"fiftyTwoWeekLow":50.9,"fiftyTwoWeekRange":"50.9 - 86.7","fiftyDayAverage":79.03,"twoHundredDayAverage":67.19,"beta":0.29,"enterpriseValue":4049527330.342426,"forwardPE":15.6,"priceToBook":4.57,"priceToSales":4.09,"enterpriseToRevenue":4.66,"enterpriseToEbitda":17.73,"pegRatio":0,"ebitda":228429906.72480002,"ebitdaMargin":26.3,"freeCashflow":96141205.6843896,"operatingCashflow":218549065.5954,"totalDebt":142314252.4503,"debtToEquity":18,"currentRatio":3.13,"returnOnAssets":12.1,"returnOnEquity":22.3,"analystRating":"2.0 - Buy","recommendationKey":"buy","numberOfAnalysts":9,"targetMeanPrice":82.3,"targetHighPrice":100,"targetLowPrice":67,"dividendRate":0.94,"payoutRatio":0.4,"fiveYearAvgDividendYield":1.59,"exDividendDate":1752451200,"insiderHeldPercent":68,"institutionHeldPercent":19.5,"sharesOutstanding":51149498,"floatShares":16296230,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":2.36,"epsForward":3.8,"revenuePerShare":14.54,"bookValue":12.99,"officers":[{"age":null,"name":"Mr. Juan  Lopez-Belmonte Encina","title":"Chairman & CEO"},{"age":null,"name":"Mr. Ivan Jorge Lopez-Belmonte Encina","title":"Second Deputy Chairman and Chief Commercial & Development Officer"},{"age":null,"name":"Mr. Javier  Lopez-Belmonte Encina","title":"First Deputy Chairman, GM of Industrial Operations & CFO"},{"age":null,"name":"Ms. María Álvarez Solas","title":"Chief Operating Officer"},{"age":null,"name":"Ms. Marta Campos Martínez","title":"Head of Investor Relations"},{"age":null,"name":"Ms. Mercedes Benítez del Castillo Sánchez","title":"Chief Legal Officer"},{"age":null,"name":"Ms. Alicia Hurtado Morales","title":"Chief Compliance Officer"},{"age":null,"name":"Ms. Rosario  Perucha Pérez","title":"Marketing Director"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"http://www.rovi.es/inversores/inicio.php","website":"https://www.rovi.es","phone":"34 91 021 30 00"}}